

## Therapeutic Class Overview

### Calcitonin gene related peptide (CGRP) inhibitors

#### INTRODUCTION

- Migraine is a common, recurrent, incapacitating disorder characterized by moderate to severe headaches and disabling features, including nausea, vomiting, neurologic symptoms, photophobia, and phonophobia. Cluster headache is less prevalent than migraine and characterized by attacks of severe, unilateral pain with ipsilateral autonomic symptoms, which occur every other day to multiple times daily during a cluster period (*International Headache Society [IHS] 2018, Starling et al 2015*).
  - The goals for treatment of migraine are to reverse or stop the progression of a migraine attack. The goals for preventive treatment are to reduce the frequency, severity and duration of a migraine (*American Headache Society [AHS] 2019, Katsarava et al 2012*).
- The International Classification of Headache Disorders (ICHD) includes both cluster headache and migraine as part of a group of primary headache disorders (*IHS 2018*):
  - Chronic migraine is defined as  $\geq 15$  headache days per month for  $> 3$  months with the features of migraine headache for at least 8 mean migraine days per month (MMD). The most common cause of symptoms suggestive of chronic migraine is medication overuse. According to the ICHD, around 50% of patients apparently with chronic migraine revert to an episodic migraine type after drug withdrawal; such patients are in a sense wrongly diagnosed with chronic migraine. In most clinical trials, migraine that is not chronic (ie,  $< 15$  headache days per month) is considered to be episodic migraine, although the condition is not clearly defined in the ICHD.
  - Cluster headache is defined as  $\geq 5$  attacks lasting 15 to 180 minutes every other day to 8 times a day with severe unilateral orbital, supraorbital, and/or temporal pain. Episodic cluster headache attacks occur for a period of 7 days to 1 year and are separated by pain-free periods lasting at least 3 months. Common symptoms include nasal congestion, rhinorrhea, conjunctival injection and/or lacrimation, eyelid edema, sweating (forehead or face), miosis, ptosis, and/or a sense of restlessness or agitation.
- Cluster headache is more likely to occur in men, whereas migraines are more likely to occur in women. Migraines have a global prevalence of 15 to 18% and are a leading cause of disability worldwide. Chronic migraine is estimated to occur in 2 to 8% of patients with migraine, whereas episodic migraine occurs in more than 90% of patients. Cluster headache is rare compared to other primary headache disorders. It is estimated to have a prevalence of 0.1% within the general population (*Global Burden of Disease Study [GBD] 2016, Hoffman et al 2018, Lipton et al 2016, Ljubisavljevic et al 2019, Manack et al 2011*).
- Treatments for migraines and cluster headache are divided into acute and preventive therapies. Evidence and reputable guidelines clearly delineate appropriate therapies for episodic migraine treatment and prophylaxis; options stretch across a wide variety of therapeutic classes and are usually oral therapies. For the prevention of migraines, treatment options include oral prophylactic therapies, injectable prophylactic therapies, and neuromodulator devices. Oral prophylactic migraine therapies have modest efficacy, and certain oral therapies may not be appropriate for individual patients due to intolerability or eventual lack of efficacy. For the treatment of acute migraine, options include triptans, ergots, nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, small molecule CGRP inhibitors, and a 5-hydroxytryptamine (5-HT)<sub>1F</sub> receptor agonist. For the treatment of cluster headache, subcutaneous sumatriptan, zolmitriptan nasal spray, and oxygen have the most positive evidence for acute therapy, and suboccipital steroid injections are most effective for prevention (*American Migraine Foundation [AMF] 2020, Marmura et al 2015, Robbins et al 2016, Silberstein et al 2012, Simpson et al 2016 [guideline reaffirmed in 2019]*).
- The calcitonin gene-related peptide (CGRP) pathway is important in pain modulation and the Food and Drug Administration (FDA) has approved 6 CGRP inhibitors for prevention or treatment of migraine/headache disorder(s). Erenumab-aooe is a fully human monoclonal antibody, which potently binds to the CGRP receptor in a competitive and reversible manner with greater selectivity than to other human calcitonin family receptors. Fremanezumab-vfrm, eptinezumab-jjmr, and galcanezumab-gnlm are humanized monoclonal antibodies that bind to the CGRP ligand and block its binding to the receptor. Rimegepant and ubrogepant are small molecule oral CGRP receptor antagonists (*Dodick et al 2018[b], Edvinsson 2017, Goadsby et al 2017, Sun et al 2016, Tepper et al 2017*).
  - Two CGRP inhibitors known as the “gepants,” telcagepant and olcegepant, were previously investigated. In 2009, Merck withdrew the FDA application for telcagepant because of elevated liver enzymes and potential liver toxicity

observed with chronic use, which was likely related to the chemical structure of the compound. The manufacturer of olcegepant also ceased pursuing FDA approval; however, the manufacturer did not explicitly state the rationale. It has been widely speculated that olcegepant development ceased due to limitations associated with administration as an intravenous (IV)-only product (*Edvinsson et al 2017, Walker et al 2013*). No substantial issues with liver toxicity have been observed in trials with the currently marketed CGRP inhibitors.

- In April 2019, Teva announced that it would not pursue development of fremanezumab-vfrm for an episodic cluster headache indication due to results from the ENFORCE trial (*Teva Pharmaceuticals press release 2019*). Erenumab-aooe is not currently under clinical investigation for the indication of cluster headache; however, a trial has been initiated with eptinezumab-jjmr (*Clinicaltrials.gov 2021*).
- A CGRP inhibitor early in development is zavegepant, the first intranasally administered CGRP inhibitor in Phase 2/3 studies (*Biohaven Pharmaceutical 2021*). Atogepant, another oral CGRP inhibitor, was submitted for FDA approval in March 2021, with a decision anticipated for Q3 of 2021 (*AbbVie 2021*).
- Medispan class: Migraine products – monoclonal antibodies; Calcitonin gene-related peptide (CGRP) receptor antagonists

**Table 1. Medications Included Within Class Review**

Drug	Generic Availability
Aimovig (erenumab-aooe)	-
Ajovy (fremanezumab-vfrm)	-
Nurtec ODT (rimegepant sulfate)	-
Emgality (galcanezumab-gnlm)	-
Ubrelvy (ubrogepant)	-
Vyepti (eptinezumab-jjmr)	-

(*Drugs@FDA 2021, Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations 2021; Purple Book: Licensed Biological Products 2021*)

## INDICATIONS

**Table 2. Food and Drug Administration Approved Indications**

Indication	Aimovig (erenumab-aooe)	Ajovy (fremanezumab-vfrm)	Emgality (galcanezumab-gnlm)	Nurtec ODT (rimegepant)	Ubrelvy (ubrogepant)	Vyepti (eptinezumab-jjmr)
Acute treatment of migraine with or without aura in adults	-	-	-	✓	✓*	-
Preventive treatment of migraine in adults	✓	✓	✓	-	-	✓
Preventive treatment of episodic migraine in adults	⚡	⚡	⚡	✓	⚡	⚡
Treatment of episodic cluster headache in adults	-	-	✓	-	-	-

\* Limitation of use: Not indicated for the preventive treatment of migraine.

(*Prescribing information: Aimovig 2021, Ajovy 2021, Emgality 2019, Nurtec ODT 2021, Ubrelvy 2021, Vyepti 2020*)

- Information on indications, mechanism of action, pharmacokinetics, dosing, and safety has been obtained from the prescribing information for the individual products, except where noted otherwise.

## CLINICAL EFFICACY SUMMARY

### Prevention of episodic migraine

#### *Eptinezumab-jjmr*

- PROMISE-1 was a double-blind (DB), placebo-controlled (PC), multi-center (MC), Phase 3 trial in which adults with a history of episodic migraine were randomized to receive placebo (n = 222), eptinezumab-jjmr 100 mg (n = 221), or eptinezumab-jjmr 300 mg (n = 222) every 3 months for 12 months. The primary efficacy endpoint was the change in MMD from baseline to week 12. Eptinezumab-jjmr 100 mg and 300 mg significantly reduced MMDs across weeks 1 to 12 compared with placebo (placebo, -3.2; 100 mg, -3.9, p = 0.02; 300 mg, -4.3, p = 0.0001). The odds for a 50% reduction in MMD were approximately 1.7 to 2.2 times higher with eptinezumab-jjmr than placebo. Of note, the endpoints underwent a testing hierarchy and were not significant for 50% migraine responder rates in the 100 mg dose group (*Ashina et al 2020, Vyepti [dossier] 2020*).
  - The reduction in MMD was sustained through 1 year of follow-up for the eptinezumab-jjmr 300 mg group (-5.3 days), which was significant compared to placebo (-4.1 days) at weeks 37 to 48 (difference, -1.2; 95% CI, -1.95 to -0.46). The reduction in the 100 mg group was significantly greater compared to placebo at 25 to 36 weeks (-4.7 vs -4.0, respectively; difference, -0.72; 95% CI, -1.43 to -0.01), but not at 37 to 48 weeks (-4.5 vs -4.1; difference -0.38; 95% CI, -1.13 to 0.37) (*Smith et al 2020*).

#### *Erenumab-aooe*

- The STRIVE trial was a 6-month, DB, PC, MC, Phase 3 trial in which 955 patients with episodic migraine were randomized to placebo (n = 319), erenumab-aooe 70 mg (n = 317), or erenumab-aooe 140 mg (n = 319) once monthly. The primary endpoint was the change in mean MMD from baseline to months 4 to 6, which favored treatment with erenumab-aooe 70 mg (mean change vs placebo, -1.4; 95% confidence interval [CI], -1.9 to -0.9; p < 0.001) and erenumab-aooe 140 mg (mean change vs placebo, -1.9; 95% CI, -2.3 to -1.4; p < 0.001). Erenumab-aooe significantly increased the proportion of patients achieving ≥ 50% reduction in MMD (difference for 70 mg vs placebo, 16.7%; odds ratio [OR], 2.13; difference for 140 mg vs placebo, 23.4%; OR, 2.81). Erenumab-aooe was also associated with a significant decrease in the mean monthly acute migraine-specific medication treatment days (difference for 70 mg vs placebo, -0.9; difference for 140 mg vs placebo, -1.4) (*Goadsby et al 2017*). Data after 1 year of treatment found sustained efficacy in episodic migraine (*Goadsby et al 2020[a]*).
- The ARISE trial was a 12-week, DB, PC, MC, Phase 3 trial in which 577 patients with episodic migraine were randomized to placebo (n = 291) or erenumab-aooe 70 mg (n = 286) once monthly. The primary endpoint was the change in MMD from baseline to weeks 9 to 12, which favored treatment with erenumab-aooe 70 mg (mean change vs placebo, -1.0; 95% CI, -1.6 to -0.5; p < 0.001). Compared to placebo, erenumab-aooe significantly increased the proportion of patients achieving ≥ 50% reduction in MMD (difference, 10.2%; OR, 1.59). Erenumab-aooe was also associated with a significant decrease in the mean monthly acute migraine-specific medication treatment days (difference, -0.6) (*Dodick et al 2018[a]*).
- The LIBERTY trial was a 12-week, DB, PC, MC, Phase 3b trial in which 246 patients with episodic migraine who failed 2 to 4 prior preventive migraine treatments were randomized to placebo (n = 125) or erenumab-aooe 140 mg (n = 121) once monthly. The primary endpoint was the proportion of patients with ≥ 50% reduction in MMD from baseline to the last 4 weeks of DB treatment (weeks 9 to 12), which erenumab-aooe significantly increased over placebo (difference, 16.6%; OR, 2.73; 95% CI, 1.43 to 5.19; p = 0.002). Compared to placebo, 5.9% more patients treated with erenumab-aooe 140 mg reported a 100% reduction in MMD, or migraine cessation. Erenumab-aooe 140 mg/month compared with placebo significantly reduced the MMD (difference, -1.61; 95% CI, -2.70 to -0.52; p = 0.004). Erenumab-aooe was also associated with a significant decrease in the mean monthly acute migraine-specific medication treatment days (difference, -1.73) (*Reuter et al 2018*).

#### *Fremanezumab-vfrm*

- The HALO-EM trial was a 12-week, DB, PC, MC, Phase 3 trial in which 875 patients with episodic migraine were randomized to placebo (n = 294), fremanezumab-vfrm 225 mg once monthly (n = 290), or fremanezumab-vfrm 675 mg once quarterly (n = 291). The primary endpoint was the change in mean MMD, which favored treatment with fremanezumab-vfrm 225 mg (mean change vs placebo, -1.5; 95% CI, -2.0 to -0.9; p < 0.001) and fremanezumab-vfrm 675 mg (mean change vs placebo, -1.3; 95% CI, -1.8 to -0.7; p < 0.001). Of note, HALO-EM was powered to detect a 1.6-day difference in the MMD between the fremanezumab-vfrm and placebo groups, but effect sizes resulted in a 1.5-day reduction for the fremanezumab-vfrm monthly dosing group and a 1.3-day reduction for the fremanezumab-vfrm

quarterly dosing group. Although the threshold was not reached, a minimal clinically important difference has not been established for this particular outcome. Compared to placebo, greater MMD reductions were also observed in patients who were prescribed fremanezumab-vfrm 225 mg (mean change vs placebo, -1.3) and 675 mg (mean change vs placebo, -1.1) as monotherapy. Fremanezumab-vfrm significantly increased the proportion of patients achieving  $\geq 50\%$  reduction in MMD (difference for 225 mg vs placebo, 19.8%; OR, 2.36; difference for 675 mg vs placebo, 16.5%; OR, 2.06). Additionally, fremanezumab-vfrm was associated with a significant decrease in the mean monthly acute migraine-specific medication treatment days (difference for 225 mg vs placebo, -1.4; difference for 675 mg vs placebo, -1.3) (*Dodick et al 2018[b]*). Data after 1 year of treatment found sustained efficacy in episodic migraine (*Goadsby et al 2020[b]*).

- FOCUS was a DB, PC, Phase 3b trial that evaluated 838 patients with episodic (39%) or chronic migraine (61%) who had previously not responded to 2 to 4 classes of migraine preventive medications. Of the patients enrolled, approximately 40% were classified as having episodic migraines and randomized to fremanezumab-vfrm 225 mg administered monthly with no loading dose ( $n = 110/283$ ), fremanezumab-vfrm 675 mg administered quarterly ( $n = 107/276$ ), or placebo ( $n = 112/279$ ) for 12 weeks. Failure was defined as no clinically meaningful improvement after at least 3 months of therapy at a stable dose, as per the treating physician's judgment, discontinuation because of adverse events that made treatment intolerable, or treatment contraindicated or unsuitable for the preventive treatment of migraine for the patient. At baseline, the MMD was approximately 14.2 days and the MMHD (of at least moderate severity) was 12.6 days. For the overall population, the MMD reduction over 12 weeks was 0.6 (standard error [SE], 0.3) days for placebo, 4.1 (SE, 0.34) days for the monthly fremanezumab-vfrm group (least squares mean difference [LSMD] vs placebo, -3.5; 95% CI, -4.2 to -2.8 days;  $p < 0.0001$ ), and 3.7 (SE, 0.3) for days for the quarterly fremanezumab-vfrm group (LSMD vs placebo, -3.1; 95% CI, -3.8 to -2.4 days;  $p < 0.0001$ ). For episodic migraine and compared to placebo, the LSMD in MMD reduction over 12 weeks was 3.1 days for both dose groups (fremanezumab-vfrm monthly: LSMD, -3.1; 95% CI, -4.0 to -2.3 days; fremanezumab-vfrm quarterly: LSMD, -3.1; 95% CI, -3.9 to -2.2 days;  $p < 0.0001$  for both). In the overall population, the proportions of patients with a  $\geq 50\%$  response over 12 weeks were 34% in both the quarterly and monthly fremanezumab-vfrm groups vs 9% with placebo ( $p < 0.0001$ ). Only the monthly fremanezumab-vfrm arm achieved a  $\geq 75\%$  sustained responder rate that was statistically different from placebo (OR, 8.6; 95% CI, 2.0 to 37.9;  $p = 0.0045$ ). Adverse events were similar for placebo and fremanezumab-vfrm. Serious adverse events were reported in 4 (1%) of 277 patients with placebo, 4 (1%) of 285 with monthly fremanezumab-vfrm, and 2 (< 1%) of 276 with quarterly fremanezumab-vfrm (*Ferrari et al 2019*).

#### Galcanezumab-gnlm

- The EVOLVE-1 and EVOLVE-2 trials were 6-month, DB, PC, MC, Phase 3 trials in 858 and 915 patients with episodic migraine, respectively. Patients were randomized to placebo (EVOLVE-1,  $n = 433$ ; EVOLVE-2,  $n = 461$ ), galcanezumab-gnlm 120 mg once monthly (EVOLVE-1,  $n = 213$ ; EVOLVE-2,  $n = 231$ ), or galcanezumab-gnlm 240 mg once monthly (EVOLVE-1,  $n = 212$ ; EVOLVE-2,  $n = 223$ ). Patients in the galcanezumab-gnlm 120 mg group received a loading dose of 240 mg at the first injection only. The EVOLVE-1 trial included a North American population and the EVOLVE-2 trial included a global population. The primary endpoint was the change in mean monthly migraine headache days (MMHD) (*Stauffer et al 2018, Skljarevski et al 2018*).
  - In EVOLVE-1, the primary endpoint outcome favored treatment with galcanezumab-gnlm 120 mg (mean change vs placebo, -1.9; 95% CI, -2.5 to -1.4;  $p < 0.001$ ) and galcanezumab-gnlm 240 mg (mean change vs placebo, -1.8; 95% CI, -2.3 to -1.2;  $p < 0.001$ ). Galcanezumab-gnlm significantly increased the proportion of patients achieving  $\geq 50\%$  reduction in MMHD (difference for 120 mg vs placebo, 23.7%; OR, 2.64; difference for 240 mg vs placebo, 22.3%; OR, 2.50). Compared to placebo, 9.4% more patients treated with galcanezumab-gnlm 120 mg and 9.4% more treated with galcanezumab-gnlm 240 mg reported a 100% reduction in MMHD, or migraine cessation. Galcanezumab-gnlm was also associated with a significant decrease in the mean monthly acute migraine-specific medication treatment days (difference for 120 mg vs placebo, -1.8; difference for 240 mg vs placebo, -1.6) (*Stauffer et al 2018*).
  - In EVOLVE-2, the primary endpoint outcome favored treatment with galcanezumab-gnlm 120 mg (mean change vs placebo, -2.0; 95% CI, -2.6 to -1.5;  $p < 0.001$ ) and galcanezumab-gnlm 240 mg (mean change vs placebo, -1.9; 95% CI, -2.4 to -1.4;  $p < 0.001$ ). Galcanezumab-gnlm significantly increased the proportion of patients achieving  $\geq 50\%$  reduction in MMHD (difference for 120 mg vs placebo, 23.0%; OR, 2.54; difference for 240 mg vs placebo, 21.0%; OR, 2.34). Compared to placebo, 5.8% more patients treated with galcanezumab-gnlm 120 mg and 8.1% more treated with galcanezumab-gnlm 240 mg reported migraine cessation. Galcanezumab-gnlm was also

associated with a significant decrease in the mean monthly acute migraine-specific medication treatment days (difference for 120 mg vs placebo, -1.8; difference for 240 mg vs placebo, -1.7) (Skljarevski et al 2018).

- In an analysis of persistence for patients with episodic migraine, 41.5 and 41.1% of galcanezumab-gnlm-treated patients (120 mg and 240 mg, respectively) had a  $\geq 50\%$  response for  $\geq 3$  months, which was greater than placebo (21.4%;  $p < 0.001$ ). Approximately 6% of galcanezumab-gnlm-treated patients maintained  $\geq 75\%$  response all 6 months vs 2% of placebo-treated patients. Few galcanezumab-gnlm-treated patients maintained 100% response for all 6 months ( $< 1.5\%$ ) (Förderreuther et al 2018).
- CONQUER was a DB, PC, Phase 3b trial that evaluated 462 patients with episodic (58%) or chronic migraine (42%) who had previously not responded to 2 to 4 classes of migraine preventive medications for 12 weeks. All galcanezumab-gnlm patients were administered a 240 mg loading dose, then 120 mg per month. Failure was defined as discontinuation owing to no response or inadequate response, or safety or tolerability event. At baseline, the MMHD was approximately 13.2 days with 9.3 in the episodic migraine group and 18.7 in the chronic migraine group. For the overall population, the MMHD reduction over 12 weeks was 1.0 (SE, 0.3) days for placebo, 4.1 (SE, 0.3) days for the monthly galcanezumab-gnlm group (LSMD, -3.1; 95% CI, -3.9 to -2.3 days;  $p < 0.0001$ ). For episodic migraine and compared to placebo, the LSMD in MMHD reduction over 12 weeks was 2.6 days for the galcanezumab-gnlm monthly group (95% CI, -3.4 to -1.7 days;  $p < 0.0001$ ). In the overall population, the proportions of patients with a  $\geq 50\%$  response over 12 weeks were 41.8% in the monthly galcanezumab-gnlm group vs 17.1% with placebo ( $p < 0.0001$ ). Compared to placebo, the monthly galcanezumab-gnlm arm achieved a statistically significant improvement of  $\geq 75\%$  sustained responder (3.7 vs 18.4%; OR, 5.9; 95% CI, 2.4 to 14.6;  $p = 0.0001$ ) and 100% sustained responder (0 vs 7.7%;  $p < 0.0001$ ). Treatment-emergent adverse events were similar for placebo and galcanezumab-gnlm (53 vs 51%). Serious adverse events were reported in 2 patients (1%) of each of the groups (Mulleners et al 2020).
  - A post-hoc analysis evaluated the time to treatment onset, which showed a significant reduction in headache days with galcanezumab-gnlm beginning during the first month, which was significant compared to placebo (-4.0 vs -0.7, respectively;  $p \leq 0.001$ ). There was also a significantly greater reduction in weekly headache days with galcanezumab-gnlm beginning week 1 compared to placebo (-1.1 vs -0.2;  $p < 0.01$ ) (Schwedt et al 2021).

#### Rimegepant

- Rimegepant was studied in a MC, DB, PC, Phase 2/3 trial in adults with migraine for  $\geq 1$  year and with 4 to 18 moderate-to-severe migraine attacks per month. A total of 747 adults with  $\geq 6$  migraine days were randomized to rimegepant 75 mg ( $n = 370$ ) orally every other day vs placebo ( $n = 371$ ) for 12 weeks. Patients were allowed to continue 1 preventive medication excluding another CGRP inhibitor (ie, topiramate, gabapentin, beta-blockers, and tricyclic antidepressants), and rescue medication (ie, triptans, NSAIDs, paracetamol, aspirin, caffeine, baclofen, antiemetics, and muscle relaxants). At baseline, patients had a mean of 7.8 moderate-to-severe attacks per month, 40% with aura, and 23% had a history of chronic migraine. After 12 weeks of treatment, a reduction from observation period in MMD during weeks 9 to 12 was 4.3 vs 3.5 days for rimegepant vs placebo, respectively ( $p = 0.0099$ ). A  $\geq 50\%$  reduction in moderate-to-severe MMDs during weeks 9 to 12 were observed in 49 vs 41% for rimegepant vs placebo, respectively ( $p = 0.044$ ). A reduction in mean number of total migraine days per month during weeks 1 to 12 was 3.6 vs 2.7 days, respectively ( $p = 0.0017$ ). Treatment related adverse events were reported in 11% in the rimegepant arm vs 9% in the placebo arm. All other incidences of adverse events were similar between groups. Most common adverse events included nausea, nasopharyngitis, urinary tract infection, and upper respiratory tract infection (Croop et al 2021).

### Prevention of chronic migraine

#### Eptinezumab-jjmr

- The PROMISE-2 trial was a 12-week, DB, PC, MC, Phase 3 trial in which 1121 patients with chronic migraine were randomized to placebo ( $n = 366$ ), eptinezumab-jjmr 100 mg ( $n = 356$ ), or eptinezumab-jjmr 300 mg ( $n = 350$ ) once every 12 weeks (or quarterly). The primary endpoint was the change in mean MMD. Treatment with eptinezumab 100 and 300 mg was associated with significant reductions in MMDs across weeks 1 to 12 compared with placebo (placebo -5.6; 100 mg -7.7,  $p < 0.0001$ ; 300mg -8.2,  $p < 0.0001$ ). The odds for a 50% reduction in MMD were approximately 2.1 to 2.4 times higher with eptinezumab-jjmr than placebo (Lipton et al 2020[a]). Updated data from PROMISE-2 demonstrated similar responses at 24 weeks as were observed at 12 weeks (Silberstein et al 2020[a]).
- The PREVAIL trial was an OL, single-arm, Phase 3 trial evaluating long-term outcomes for eptinezumab-jjmr for 2 years. A total of 128 adults with chronic migraine received eptinezumab-jjmr 300 mg every 12 weeks for up to 8 doses. The percentage of patients with severe disability measured using the Migraine Disability Assessment tool (MIDAS) decreased from 84.4% to 26.8% at 12 weeks and 20.8% at week 104 (Kudrow et al 2021).

### Erenumab-aooe

- Erenumab-aooe was studied in a 12-week, DB, PC, MC, Phase 2 trial in which 667 patients with chronic migraine were randomized to placebo (n = 286), erenumab-aooe 70 mg (n = 191), or erenumab-aooe 140 mg (n = 190) once monthly. The primary endpoint was the change in MMD from baseline to weeks 9 to 12, which favored treatment with erenumab-aooe 70 mg and erenumab-aooe 140 mg (mean change for both doses vs placebo, -2.5; 95% CI, -3.5 to -1.4; p < 0.0001). Erenumab-aooe significantly increased the proportion of patients achieving ≥ 50% reduction in MMD (difference for 70 mg vs placebo, 17%; OR, 2.2; difference for 140 mg vs placebo, 18%; OR, 2.3). Both erenumab-aooe 70 mg (difference, -1.9) and erenumab-aooe 140 mg (difference, -2.6) significantly reduced the mean acute migraine-specific medication days; however, the higher 140 mg dose had a greater reduction numerically over placebo and reductions may be dose-dependent (*Tepper et al 2017*).
  - An analysis of patient reported outcomes found patients with chronic migraine had clinically relevant improvements across a range of measures. Improvements were observed at month 3 for all endpoints regardless of erenumab-aooe dose, and minimally important clinical differences were achieved for certain measures with the erenumab-aooe 140 mg dose (*Lipton et al 2019[b]*).

### Fremanezumab-vfrm

- Fremanezumab-vfrm was studied in a 12-week, DB, PC, MC, Phase 3 trial, HALO-CM, in which 1130 patients with chronic migraine were randomized to placebo (n = 375), fremanezumab-vfrm 225 mg once monthly (n = 379), or fremanezumab-vfrm 675 mg once quarterly (n = 376). Patients in the fremanezumab-vfrm 225 mg group received a loading dose of 675 mg at the first injection only. The primary endpoint was the change in mean headache days (MHD), which favored treatment with fremanezumab-vfrm 225 mg (mean change vs placebo, -2.1; SE, ± 0.3; p < 0.001) and fremanezumab-vfrm 675 mg (mean change vs placebo, -1.8; SE, ± 0.3; p < 0.001). Fremanezumab-vfrm significantly increased the proportion of patients achieving ≥ 50% reduction in MHD (difference for 225 mg vs placebo, 22.7%; OR, 2.73; difference for 675 mg vs placebo, 19.5%; OR, 3.13). Additionally, fremanezumab-vfrm was associated with a significant decrease in the mean monthly acute migraine-specific medication treatment days (difference for 225 mg vs placebo, -2.3; difference for 675 mg vs placebo, -1.8) (*Silberstein et al 2017*). Data after 1 year of treatment found sustained efficacy in chronic migraine (*Goadsby et al 2020[b]*).
  - A subgroup analysis evaluated the proportion of patients reverting to episodic migraine, defined as < 15 headache days per month. A total of 44.5% of patients in the placebo group reverted to episodic migraine compared to 50.5% in the quarterly fremanezumab-vfrm group (p = 0.108) and 53.7% in the monthly dosing group (p = 0.012) (*Lipton et al 2020[b]*).
- FOCUS was previously described as including 838 patients overall who had not responded to 2 to 4 classes of migraine preventive medications. Of the patients enrolled, 61% were diagnosed with chronic migraine and were randomized to fremanezumab-vfrm 675 mg administered quarterly (n = 169/276), a fremanezumab-vfrm 675 mg loading dose followed by 225 mg administered monthly (n = 173/283), or placebo (n = 167/279). Among patients classified as having chronic migraine and compared to placebo, the LSMD in MMD reduction over 12 weeks was 3.8 days for the fremanezumab-vfrm monthly group and 3.2 days for the fremanezumab-vfrm quarterly group (fremanezumab-vfrm monthly: LSMD, -3.8; 95% CI, -4.8 to -2.8 days; fremanezumab-vfrm quarterly: LSMD, -3.2; 95% CI, -4.2 to -2.2 days; p < 0.0001 for both) (*Ferrari et al 2019*).

### Galcanzumab-gnlm

- Galcanzumab-gnlm was evaluated in a 12-week, DB, PC, MC, Phase 3 trial, REGAIN, in which 1113 patients with chronic migraine were randomized to placebo (n = 558), galcanzumab-gnlm 120 mg once monthly (n = 278), or galcanzumab-gnlm 240 mg once monthly (n = 277). Patients in the galcanzumab-gnlm 120 mg group received a loading dose of 240 mg at the first injection only. The primary endpoint was the change in MMHD, which favored treatment with galcanzumab-gnlm 120 mg (mean change vs placebo, -2.1; 95% CI, -2.9 to -1.3; p < 0.001) and galcanzumab-gnlm 240 mg (mean change vs placebo, -1.9; 95% CI, -2.7 to -1.1; p < 0.001). Galcanzumab-gnlm significantly increased the proportion of patients achieving ≥ 50% reduction in MMHD (difference for 120 mg vs placebo, 12.2%; OR, 2.10; difference for 240 mg vs placebo, 12.1%; OR, 2.10). Compared to placebo, 0.2% more patients treated with galcanzumab-gnlm 120 mg and 0.8% more treated with galcanzumab-gnlm 240 mg reported migraine cessation; this was not statistically different for either dose group. Galcanzumab-gnlm was also associated with a significant decrease in the mean monthly acute migraine-specific medication treatment days (difference for 120 mg vs placebo, -2.5; difference for 240 mg vs placebo, -2.1) (*Detke et al 2018*).
  - In an analysis of persistence for patients with chronic migraine, 29% of galcanzumab-gnlm-treated patients maintained ≥ 30% response all 3 months compared to 16% of placebo-treated patients. A total of 16.8 and 14.6%

of galcanezumab-gnlm-treated patients (120 mg and 240 mg, respectively) had a  $\geq 50\%$  response for  $\geq 3$  months, which was greater than placebo (6.3%;  $p < 0.001$ ). Few patients maintained  $\geq 75\%$  response ( $< 3\%$ ) (Förderreuther et al 2018).

- CONQUER was previously described as including 462 patients overall who had not responded to 2 to 4 classes of migraine preventive medications. Of the patients enrolled, 42% were diagnosed with chronic migraine and were randomized to galcanezumab-gnlm 240 mg loading dose followed by 120 mg administered monthly ( $n = 95/193$ ), or placebo ( $n = 98/193$ ). Among patients classified as having chronic migraine and compared to placebo, the LSMD in MMHD reduction over 12 weeks was 3.7 days for the galcanezumab-gnlm monthly group (95% CI, -5.2 to -2.2 days;  $p < 0.0001$ ) (Mulleners et al 2020).

### Treatment of episodic cluster headache

#### *Galcanezumab-gnlm*

- Galcanezumab-gnlm was evaluated in an 8-week, DB trial, in which 106 patients with episodic cluster headache were randomized to placebo ( $n = 57$ ) or galcanezumab-gnlm 300 mg once monthly ( $n = 49$ ). A total of 90 (85%) patients completed the DB phase. Patients were allowed to use certain specified acute/abortive cluster headache treatments, including triptans, oxygen, acetaminophen (APAP), and NSAIDs during the study. At baseline, patients had a mean of 17.5 headache attacks/week, maximum of 8 attacks/day, minimum of 1 attack every other day, and at least 4 attacks during the prospective 7-day baseline period. For the primary endpoint, galcanezumab-gnlm significantly decreased the mean change from baseline in weekly cluster headache attack frequency during weeks 1 to 3 vs placebo (-8.7 vs -5.2 attacks;  $p = 0.036$ ). Galcanezumab-gnlm was also associated with a significantly greater proportion of responders ( $\geq 50\%$  reduction in weekly cluster headache attack frequency) at week 3 (71.4 vs 52.6%;  $p = 0.046$ ). Adverse events did not differ between groups, except for a significant increase in the incidence of injection-site pain with galcanezumab-gnlm treated patients (8 vs 0%;  $p = 0.04$ ) (Clinicaltrials.gov [NCT02397473] 2021, Emgality prescribing information 2019, Goadsby et al 2019).

### Treatment of acute migraine (with or without aura)

#### *Rimegepant ODT*

- Rimegepant ODT was evaluated in a Phase 3, DB, MC, PC, randomized controlled trial (RCT) in 1466 patients (modified intention to treat,  $n = 1351$ ) with migraine with or without aura. Patients were randomized to placebo ( $n = 682$ ) or rimegepant ODT 75 mg ( $n = 669$ ) and were not allowed a second dose of study treatment. Rescue medications allowed 2 hours post-dose included aspirin, ibuprofen, naproxen (or any other type of NSAID), APAP up to 1000 mg/day, antiemetics (eg, metoclopramide or promethazine), or baclofen. Approximately 14% of patients were taking preventive medications for migraine at baseline. The co-primary endpoints were pain freedom and most bothersome symptom (MBS) freedom at 2 hours post-dose. Among patients randomized, 92.2% were included in the efficacy analysis and 93.8% in the safety analysis (Croop et al 2019, Nurtec ODT [dossier] 2020, Nurtec ODT prescribing information 2020).
  - The percentage of patients achieving headache pain freedom and MBS freedom 2 hours after a single dose was statistically significantly greater in patients who received rimegepant ODT compared to those who received placebo.
    - *Pain-free at 2 hours*: 21.2% for rimegepant ODT 75 mg vs 10.9% for placebo ( $p < 0.0001$ )
    - *MBS-free at 2 hours*: 35.1% for rimegepant ODT 75 mg vs 26.8% for placebo ( $p = 0.0009$ )
  - Out of the 21 secondary endpoints tested hierarchically, significant results were achieved for the first 19 endpoints. Those endpoints that were considered not significant included freedom from nausea at 2 hours post-dose, and pain relapse from 2 to 48 hours.
  - The most common adverse events were nausea and urinary tract infection. No serious adverse events were reported.
- Three additional trials evaluating the efficacy and safety of rimegepant 75 mg in an oral tablet (non-ODT) formulation were considered supportive for approval.
  - A MC, DB, dose-ranging trial using an adaptive design was conducted to determine an effective and tolerable dose range of rimegepant for the acute treatment of migraine. A total of 885 adults with migraine with or without aura were randomized to 1 of 6 rimegepant dose groups (10, 25, 75, 150, 300, or 600 mg), sumatriptan 100 mg, or placebo. It was found that the proportion of patients who were pain-free 2 hours after receiving a single dose of rimegepant 75 mg oral tablet was significantly higher compared with placebo (31.4% [ $n = 27/86$ ] vs 15.3% [ $n = 31/203$ ];  $p = 0.002$ ). The most common adverse events were nausea, vomiting, and dizziness. No treatment-related serious AEs were reported (Marcus et al 2014).

- A MC, DB, PC, Phase 3 trial (n = 1072 in efficacy analysis) evaluating rimegepant vs placebo for acute migraine treatment found that the proportion of patients who were pain-free 2 hours after receiving a single dose of rimegepant 75 mg oral tablet was significantly higher compared with placebo (19.6 vs 12.0%; absolute difference, 7.6%; 95% CI, 3.3 to 11.9; p < 0.001). In addition, the proportion of patients who were free from their MBS 2 hours post-dose was significantly higher with rimegepant 75 mg oral tablet compared with placebo (37.6 vs 25.2%; absolute difference, 12.4%; 95% CI, 6.9 to 17.9; p < 0.001). Nausea and urinary tract infection were the only AEs reported in > 1% of the patients in the rimegepant and placebo groups. A serious adverse event associated with rimegepant was back pain (n = 1) (*Lipton et al 2019[c]*, *Nurtec ODT [dossier] 2020*).
- A MC, DB, PC, Phase 3 trial (n = 1084 in efficacy analysis) evaluating rimegepant vs placebo for acute migraine treatment found that the proportion of patients who were pain-free 2 hours after receiving a single dose of rimegepant 75 mg oral tablet was significantly higher compared with placebo (19.2 vs 14.2%; p = 0.03). In addition, the proportion of patients who were free from their MBS 2 hours post-dose was significantly higher with rimegepant 75 mg oral tablet compared with placebo (36.6 vs 27.7%; p = 0.002). Nausea and dizziness were the most common adverse events reported in the rimegepant and placebo treatment groups, respectively. Serious adverse events were reported in 2 patients treated with rimegepant and 1 patient treated with placebo (*Lipton et al 2018 [poster]*, *Nurtec ODT [dossier] 2020*).
- Data is emerging on the combination use of rimegepant with CGRP monoclonal antibodies. A sub-study nested within a MC, OL, long-term safety study evaluated outcomes of 13 patients on CGRP monoclonal antibodies (erenumab, n = 7; fremanezumab, n = 4; and galcanezumab, n = 2) who received rimegepant 75 mg as needed (*Berman et al 2020*). An average of 7.8 rimegepant doses were administered over a 4-week period, and 5 patients experienced mild or moderate AEs and no patients experienced severe AEs (*Berman et al 2020*; *Mullin et al 2020*). Of note, this data is only available in a very small number of patients.

#### Ubrogepant

- Ubrogepant was evaluated in 2 Phase 3, PC, DB trials (ACHIEVE I and II), in which 3358 patients (ACHIEVE I, n = 1672; ACHIEVE II, n = 1686) were randomized to take 1 dose of placebo (n = 1122), ubrogepant 50 mg (n = 1118), or ubrogepant 100 mg (n = 557) (100 mg was evaluated in the ACHIEVE I trial only, and a 25 mg group was included in the ACHIEVE II trial only [n = 561]). Patients had 2 to 8 migraines/month with moderate to severe pain intensity in the past 3 months either with or without aura and had a history of migraine for ≥ 1 year. A second dose of study treatment (placebo or ubrogepant), or the patient's usual acute treatment for migraine, was allowed between 2 to 48 hours after the initial treatment for a non-responding or recurrent migraine headache. At baseline, 23% of patients were taking preventive medications for migraine, and approximately 23 to 27% were insufficient triptan responders. In ACHIEVE I, 79% were included in the efficacy analysis and 86% in the safety analysis, and in ACHIEVE II, 91.7% had a qualifying migraine event and 88% were included in the analysis (*Dodick et al 2019*, *Lipton et al 2019[a]*, *Ubrogepant prescribing information 2021*).
- Compared to placebo, significant improvements were demonstrated for the co-primary endpoints of pain freedom and the MBS freedom at 2 hours post-dose in the ubrogepant arms. MBS was a collection of selective, self-identified symptoms (ie, photophobia, phonophobia, or nausea). The following differences from placebo were demonstrated:
  - **Pain-free at 2 hours:** 7.4% (p = 0.002) and 7.5% (p = 0.007) for the ubrogepant 50 mg dose in ACHIEVE I and II trials, respectively, and 9.4% (p < 0.001) for ubrogepant 100 mg dose in ACHIEVE I trial.
  - **MBS-free at 2 hours:** 10.8% and 11.5% (p < 0.001 for both) for the ubrogepant 50 mg dose in ACHIEVE I and II trials, respectively, and 9.9% (p < 0.001) for ubrogepant 100 mg dose in ACHIEVE I trial.
- The incidence of photo- and phonophobia was reduced following administration. Significantly more patients maintained pain freedom for 2 to 24 hours post-dose in the ubrogepant 100 mg arm (difference from placebo, 6.8%; p = 0.002) and the 50 mg arm for ACHIEVE II only (6.2%; p = 0.005).
- In ACHIEVE I, the most common adverse events included nausea (1.5 to 4.7%), somnolence (0.6 to 2.5%), and dry mouth (0.6 to 2.1%). In ACHIEVE II, the most common adverse events within 48 hours were nausea (≤ 2.5% for all arms) and dizziness (≤ 2.1% for all arms). No serious adverse events or adverse events leading to discontinuation were reported 48 hours after the initial dose. In ACHIEVE II, the serious adverse events at 30 days included appendicitis, spontaneous abortion, pericardial effusion, and seizure.

#### Treatment of medication overuse headache

##### Eptinezumab-jjmr



- A subgroup, exploratory analysis of the PROMISE-2 trial, which was previously described, evaluated eptinezumab-jjmr 100 mg (n = 139), 300 mg (n = 147), or placebo (n = 145) in patients with chronic migraine and medication overuse headache at baseline screening. Patients receiving eptinezumab-jjmr had a significantly greater reduction in MMDs compared to placebo over weeks 1 to 12 (placebo: change from baseline, -5.4; 100 mg: change from baseline, -8.4, difference from placebo, -3.0, 95% CI, -4.56 to -1.52, p < 0.0001 vs placebo; 300 mg: change from baseline, -8.6, difference from placebo, -3.2, 95% CI, -4.66 to -1.78, p < 0.0001) (*Diener et al 2021*).

#### **Erenumab-aooe**

- A subgroup analysis was performed to evaluate patients with chronic migraine and medication overuse included in a double-blind, placebo-controlled study of 667 patients, previously described by *Tepper et al*. A total of 274 patients had medication overuse at baseline screening and were randomized to erenumab-aooe 70 mg (n=79) or 140 mg (n = 78) or placebo (n = 117). At month 3, there was a significant reduction in MMD in both erenumab-aooe dosing groups (-6.6) compared to placebo (-3.5; difference, -3.1; 95% CI, -4.8 to -1.4; p < 0.001). The percentage of patients with ≥ 50% response rate was significantly higher in the 70 mg group (36%; OR, 2.67; 95% CI, 1.36 to 5.22) and the 140 mg group (35%; OR, 2.51; 95% CI, 1.28 to 4.94) compared to placebo (18%) (*Tepper et al 2019*).

#### **Fremanezumab-vfrm**

- The impact of fremanezumab-vfrm on medication overuse headaches in patients with chronic migraine was evaluated through a subgroup analysis of the HALO CM study, which was previously described. Of the 1130 patients enrolled in HALO CM, 587 had medication overuse at baseline and were randomized to fremanezumab-vfrm quarterly (n = 201), monthly (n = 198), or placebo (n = 188). Compared with placebo, the reduction in MMD was greater for patients receiving fremanezumab-vfrm quarterly (-2.5 vs -4.7; difference, -2.2; 95% CI, -3.1 to -1.2; p < 0.0001) and monthly (-2.5 vs -5.2; difference, -2.7; 95% CI, -3.7 to -1.8; p < 0.0001) (*Silberstein et al 2020[b]*).

#### **Galcanezumab-gnlm**

- A post-hoc analysis of 3 previously described Phase 3 studies in patients with episodic migraine (EVOLVE-1 and EVOLVE-2) or chronic migraine (REGAIN) evaluated the efficacy of galcanezumab-gnlm in the prevention of migraine in patients with and without medication overuse (*Dodick et al 2021*).
  - In the subgroup analysis of patients with medication overuse headaches and episodic migraine, there was a significantly greater reduction in MMD with both galcanezumab-gnlm 120 mg (-6.3; difference from placebo, -3.6; 95% CI, -4.7 to -2.4; p < 0.001) and 240 mg (-5.8; difference from placebo, -3.1; 95% CI, -4.2 to -2.0; p < 0.001) compared to placebo (-2.7).
  - In the subgroup analysis of patients with medication overuse headaches and chronic migraine, there was a significantly greater reduction in MMD with both galcanezumab-gnlm 120 mg (-4.8; difference from placebo, -2.5; 95% CI, -3.6 to -1.5; p < 0.001) and 240 mg (-5.6; difference from placebo, -2.3; 95% CI, -3.3 to -1.2; p < 0.001) compared to placebo (-2.5).

## **CLINICAL GUIDELINES**

### **Acute treatment of migraine**

- The American Headache Society (AHS) published updated consensus statement guidelines for migraine in 2018. The AHS recommends the use of APAP, NSAIDs, non-opioid analgesics, or caffeinated analgesic combinations for mild or moderate attacks. The triptans or dihydroergotamine (DHE) are recommended for moderate or severe attacks as well as for mild attacks that respond poorly to other analgesics. These guidelines do not differentiate the triptans, but recommend that non-oral routes be used when severe nausea or vomiting is present. Overall, the AHS designated the following drugs as having efficacy (*AHS 2019*):
  - Established efficacy:
    - Triptans
    - Ergotamine derivatives
    - NSAIDs (aspirin, diclofenac, ibuprofen, naproxen)
    - Opioids (butorphanol, although use is not recommended)
    - Combination medications
  - Probably effective
    - Ergotamine or other forms of DHE
    - NSAIDs (ketoprofen, ketorolac intramuscular or IV, flurbiprofen)
    - Magnesium IV

- Isometheptene compounds
- Combination medications (codeine/APAP, tramadol/APAP)
- Antiemetics (prochlorperazine, promethazine, droperidol, chlorpromazine, metoclopramide)
- The AHS recommends that rimegepant and ubrogepant may have a role in patients who have contraindications to the use of triptans or who have failed to respond to or tolerate  $\geq 2$  oral triptans, as determined by either a validated acute treatment patient reported outcome questionnaire or healthcare provider attestation. Coverage should be provided until  $\geq 2$  attacks are treated to determine efficacy and tolerability.
  - Other agents have had more established efficacy and safety relative to the newly FDA-approved migraine agents.
- There are a number of older guidelines/treatment recommendations for the treatment of migraine but, similar to the 2018 guidelines, they do not state a preference for a particular triptan or therapy (*Evers et al 2009, Francis et al 2010, Marmura et al 2015, Silberstein 2000, Silberstein et al 2012 [guideline reaffirmed in 2015]*).
- In 2019, the American Academy of Neurology (AAN) and the AHS published a guideline on the acute treatment of migraine in children and adolescents. The guideline states that there is evidence to support the efficacy of ibuprofen, APAP (in children and adolescents), and triptans (mainly in adolescents) for migraine relief, although confidence in the evidence varies between agents (*Oskoui et al 2019[a]*).
  - Of note, the CGRP inhibitors have not been adequately studied in children or adolescents and are not currently FDA-approved for use in these populations.

### **Prevention of migraine**

- According to the AAN/AHS evidence-based guideline update on the pharmacologic treatment for episodic migraine prevention in adults, the following medications are effective preventive treatment options (see Appendix A for a definition of classifications) (*Silberstein et al 2012*):
  - Level A (established efficacy and  $> 2$  Class I trials):
    - Antiepileptic drugs: divalproex sodium, sodium valproate, and topiramate
    - Beta blockers: metoprolol, propranolol, and timolol
    - Triptans (for menstrual related migraine [MRM]): for short-term prophylaxis, frovatriptan
  - Level B (probably effective and 1 Class I or 2 Class II trials):
    - Antidepressants: amitriptyline and venlafaxine
    - Beta blockers: atenolol and nadolol
    - Triptans (for MRM): for short-term prophylaxis, naratriptan and zolmitriptan
  - Level C (possibly effective and 1 Class II trial):
    - Angiotensin-converting enzyme (ACE) inhibitors: lisinopril
    - Angiotensin II receptor blockers (ARBs): candesartan
    - Alpha agonists: clonidine and guanfacine
    - Antiepileptic drugs: carbamazepine
    - Beta blockers: nebivolol and pindolol
    - Antihistamines: cyproheptadine
- The AAN recommends onabotulinumtoxin A as an effective treatment option that should be offered for chronic migraine. However, onabotulinumtoxin A is considered ineffective for the treatment of episodic migraines and should not be offered. There is insufficient evidence to compare the effectiveness of botulinum neurotoxin A with that of oral prophylactic topiramate (*Simpson et al 2016 [guideline reaffirmed in 2019]*).
- In 2019, the AAN/AHS published a guideline on the preventive treatment of migraine in pediatric patients. The guideline states that the majority of preventive medications for pediatric migraine fail to demonstrate superiority to placebo. The guidelines make the following statements and recommendations for initial therapy (see Appendix B for a definition of classifications) (*Oskoui et al 2019[b]*):
  - It is possible that cognitive behavioral therapy (CBT) alone is effective in migraine prevention.
  - There is insufficient evidence to evaluate the effects of flunarizine, nimodipine, valproate, and onabotulinumtoxinA for use in migraine prevention in children and adolescents.
  - Acknowledging the limitations of currently available evidence, use of short-term treatment trials (a minimum of 2 months) may be warranted in those who could benefit from preventive treatment (Level B).
  - Consider amitriptyline combined with cognitive behavioral therapy (CBT) (inform of the potential adverse events, including risk of suicide) (Level B).

- Consider topiramate (Level B). Inform of side effects including decreased efficacy when combined with oral contraceptives and the teratogenic effect in patients of childbearing potential (Level A). In patients of childbearing potential, daily folic acid is recommended (Level A).
- Consider propranolol (Level B).
  - Of note, the CGRP inhibitors have not been adequately studied in children or adolescents and are not currently FDA-approved for use in these populations.

### **Cluster headache**

- According to the AHS evidence-based guidelines for the treatment of cluster headache, there are a number of effective treatment options (AAN classifications were used for grading; see Appendix A for definitions) (*Robbins et al 2016*).
- For acute therapy of cluster headache, the following therapy options have positive evidence:
  - Level A (established efficacy and  $\geq 2$  Class I trials):
    - Certain triptans: sumatriptan subcutaneous and zolmitriptan nasal spray
    - Oxygen
  - Level B (probably effective and 1 Class I or 2 Class II trials):
    - Certain triptans: sumatriptan nasal spray and zolmitriptan oral
    - Sphenopalatine ganglion stimulation
  - Level C (possibly effective and 1 Class II trial):
    - Cocaine/lidocaine nasal spray
    - Octreotide subcutaneous
- For preventive therapy of cluster headache, the following therapy options have positive evidence:
  - Level A (established efficacy and  $\geq 2$  Class I trials):
    - Suboccipital steroid injection
  - Level B (probably effective and 1 Class I or 2 Class II trials):
    - Civamide nasal spray (not marketed in the US)
  - Level C (possibly effective and 1 Class II trial):
    - Lithium
    - Verapamil
    - Warfarin
    - Melatonin

### **SAFETY SUMMARY**

- Ubrogepant is contraindicated with concomitant use of strong CYP3A4 inhibitors.
- Eptinezumab-jjmr, erenumab-aooe, fremanezumab-vfrm, galcanezumab-gnlm, and rimegepant are contraindicated in patients with serious hypersensitivity to the active ingredient or any of the excipients. Mild to moderate hypersensitivity reactions (eg, rash, dyspnea, pruritus, urticaria) were reported in trials. Cases of anaphylaxis and angioedema have been reported post-marketing. Delayed serious hypersensitivity has occurred with rimegepant. In cases of serious or severe reactions, treatment should be discontinued.
- Warnings and precautions associated with the CGRP inhibitors include hypersensitivity reactions, **in some cases reactions were reported within hours to 1 month after administration.** Erenumab-aooe has additional warnings and precautions associated with the following:
  - Constipation with serious complications: Constipation with serious complications has been reported post-marketing. Some cases have required hospitalization, including surgery. Constipation was a common adverse event reported in up to 3% of patients. Concurrent use of medication associated with decreased gastrointestinal motility may increase the risk for severe constipation.
  - Hypertension: Post-marketing reports of the development or worsening of hypertension have emerged. Some cases required pharmacological treatment to manage or, in other cases, hospitalization. Incidences of hypertension were most frequently reported within 7 days of treatment, and most cases were reported after the first dose.
- The CGRP inhibitors generally have a similar incidence of adverse events as placebo. Very few severe adverse events and treatment discontinuations due to adverse events were reported. Across studies, adverse events were generally mild and/or similar to placebo. The most common adverse events observed in studies of injectable CGRP inhibitors included injection site reactions (subcutaneous CGRP inhibitors), constipation (erenumab-aooe only), and

nasopharyngitis and hypersensitivity (eptinezumab-jjmr only). For the oral CGRP inhibitors, ubrogepant was associated with somnolence, and both ubrogepant and rimegepant were associated with nausea.

- There are no adequate data on the risks associated in patients who are pregnant or nursing, or in adolescent or pediatric populations.

## DOSING AND ADMINISTRATION

**Table 3. Dosing and Administration**

Drug	Available Formulations	Route	Usual Recommended Frequency	Comments
Aimovig (erenumab-aooe)	Auto-injector (70 mg/mL or 140 mg/mL)	SC	<i>Prevention of migraine:</i> Once monthly (70 or 140 mg)	May be self-administered by patients in the abdomen, thigh, or back of upper arm.  Latex-sensitive patients may have an allergic reaction to the needle shield within the white cap and the gray needle cap of the syringe.  Must be refrigerated and protected from light until time of use. Once removed from the refrigerator, erenumab-aooe has a limited stability of 7 days.
Ajovy (fremanezumab-vfrm)	Auto-injector or prefilled syringe (225 mg/1.5 mL)	SC	<i>Prevention of migraine:</i> Once monthly (225 mg) or once every 3 months (675 mg)	May be self-administered by patients in the abdomen, thigh, or back of upper arm.  The prefilled syringe cap is not made with natural rubber latex.  Must be refrigerated and protected from light until time of use. <b>If necessary, fremanezumab-vfrm may be stored at room temperature for a maximum of 7 days. After removal from the refrigerator, fremanezumab-vfrm must be used within 7 days or discarded.</b>
Emgality (galcanezumab-gnlm)	Auto-injector (120 mg/mL) Prefilled syringe (100 mg/mL or 120 mg/mL)	SC	<i>Prevention of migraine:</i> 2 consecutive injections (120 mg each) as a loading dose, then once monthly (120 mg)  <i>Episodic cluster headache:</i> 3 consecutive injections (100 mg each) at onset, and then once monthly until the end of the cluster period	May be self-administered by patients in the abdomen, thigh, back of upper arm or buttocks.  The cap is not made with natural rubber latex.  Must be refrigerated and protected from light until time of use. Once removed from the refrigerator, galcanezumab-gnlm has a limited stability of 7 days.

Drug	Available Formulations	Route	Usual Recommended Frequency	Comments
Nurtec ODT (rimegepant sulfate)	ODT (75 mg)	PO	<p><i>Acute migraine treatment:</i> As needed. Maximum dose: 75 mg in 24 hours.</p> <p><i>Prevention of episodic migraine:</i> Every other day. Maximum dose: 75 mg in 24 hours.</p>	<p>The safety of using &gt; 18 doses in a 30-day period has not been established.</p> <p>Avoid concomitant administration with strong or moderate inhibitors of CYP3A4 within 48 hours, moderate or strong inducers of CYP3A, or P-gp or BCRP inhibitors.</p>
Ubrelvy (ubrogepant)	Oral tablets (50 and 100 mg)	PO	<p><i>Acute migraine treatment:</i> As needed. A second dose may be taken at least 2 hours after the initial dose. Maximum dose: 200 mg in 24 hours.</p>	<p>The safety of treating &gt; 8 migraines in a 30 day period has not been established.</p> <p>Dose adjustments are warranted with certain concomitant drugs or in cases of metabolic impairment.</p> <p>Avoid use in patients with end stage renal disease (CrCL &lt; 15 mL/min).</p> <p>Take with or without food</p>
Vyepti (eptinezumab-jjmr)	Single-dose vial (100 mg/mL)	IV	<p><i>Prevention of migraine:</i> Once every 3 months (100 or 300 mg)</p> <p>The recommended dosage is 100 mg every 3 months; some patients may benefit from a dosage of 300 mg every 3 months.</p>	<p>Dilute with 0.9% sodium chloride injection. Following dilution, eptinezumab-jjmr must be infused within 8 hours. Infuse over approximately 30 minutes.</p> <p>Administered by a healthcare provider in a healthcare setting.</p> <p>Must be refrigerated and protected from light until time of use.</p>

See the current prescribing information for full details.

**Abbreviations:** CrCL = creatinine clearance; CYP = cytochrome P450; BCRP = breast cancer resistance protein; IV = intravenous; ODT = orally disintegrating tablet; P-gp = P-glycoprotein; PO = oral; SC = subcutaneous

**Note:** With all of the CGRP inhibitors, there are no data in pregnant women or breastfed infants. A benefit/risk assessment should be taken into consideration prior to administering.

## CONCLUSION

- Migraine is a common, recurrent, incapacitating disorder characterized by moderate to severe headaches and disabling features, including nausea, vomiting, neurologic symptoms, photophobia, and phonophobia. Migraines have a spectrum of frequency and severity that can significantly affect the quality of life of patients. Cluster headache is less prevalent than migraine and characterized by attacks of severe, unilateral pain with ipsilateral autonomic symptoms, which occur every other day to multiple times daily during a cluster period. Cluster headache is more likely to occur in men, whereas migraines are more likely to occur in women.
- Rimegepant and ubrogepant are oral CGRP inhibitors indicated for acute treatment of migraine with or without aura. Rimegepant is also indicated for the prevention of episodic migraine. The injectable CGRP inhibitors eptinezumab-jjmr, erenumab-aooe, fremanezumab-vfrm, and galcanezumab-gnlm are indicated for the prevention of migraine. Galcanezumab-gnlm has an additional indication for the treatment of episodic cluster headache. No CGRP inhibitor is

FDA-approved for use in patients aged < 18 years. Eptinezumab-jjmr is the only IV formulation and requires administration in a healthcare setting.

- Guidelines divide treatment recommendations according to age, prevention or treatment, and migraine type:
  - Current evidence-based prophylactic migraine treatment options and guidance are limited for chronic migraine, and oral prophylactic medications prescribed for episodic migraine are often used for the preventive treatment of chronic migraine. Prophylactic migraine treatment options include oral agents (mainly anti-seizure agents, antidepressants, and beta blockers), injectable agents (onabotulinumtoxin A for chronic subtypes only), or neuromodulation devices for migraine or headache attacks. Certain oral therapies may not be appropriate for individual patients due to intolerability or eventual lack of efficacy. There is no optimal prophylactic migraine therapy and head-to-head trials are lacking.
  - For the treatment of cluster headache, subcutaneous sumatriptan, zolmitriptan nasal spray, and oxygen have the most positive evidence for acute therapy according to the AHS guidelines. To date, only subcutaneous sumatriptan is FDA-approved for the acute treatment of cluster headache. Additionally, sumatriptan nasal spray, zolmitriptan oral formulations, and sphenopalatine ganglion stimulation are probably effective for acute treatment per guidelines. For prevention of cluster headaches, suboccipital steroid injections are most effective according to the guidelines; however, there is no preventive medication currently FDA-approved for cluster headache.
  - For acute treatment of migraine in adults, guidelines generally recommend the use of APAP, NSAIDs, non-opioid analgesics, or caffeinated analgesic combinations for mild or moderate attacks. The triptans or DHE are recommended for moderate or severe attacks as well as for mild attacks that respond poorly to other analgesics. Recent AHS guidelines state that rimegepant and ubrogepant may have a role in patients who have contraindications to the use of triptans or who have failed to respond to or tolerate  $\geq 2$  oral triptans.
- There are no head-to-head studies with the CGRP inhibitors, and no agent is clearly superior to others. Evidence for the CGRP inhibitors have demonstrated efficacy for the respective indications:
  - Like other preventive medications for migraine, the CGRP inhibitors are not likely to render patients migraine-free. Based on 3 to 6 month data, primary endpoint reductions are similar to many oral prophylactic therapies; however, comparisons are limited as endpoints have been inconsistently defined. There are limited analyses and trials examining efficacy in patients who failed  $\geq 2$  prior preventive therapies; however, available data suggest that these patients may achieve greater reductions in migraine/headache frequency. Further research is warranted.
    - Compared to placebo, the **injectable** CGRP inhibitors when prescribed for prophylactic migraine therapy consistently demonstrated modest but statistically significant reductions in primary endpoint measures (eg, MMD, MMH, or MMHD) ranged from 0.7 to 3.5 days after 3 to 6 months of treatment. **The numbers needed to treat (NNTs) ranged from 3 to 10 in order to achieve a  $\geq 50\%$  reduction in MM(H)D. Subgroup analyses from Phase 3 CGRP inhibitor trials showed consistent benefit for prevention of migraine in patients with medication overuse headaches.**
    - **The only oral CGRP inhibitor indicated for prevention, although for only episodic migraine, had a significant reduction of 0.8 MMD after 3 months of treatment. The NNT was 13 in order to achieve a  $\geq 50\%$  reduction in moderate-to-severe MMDs.**
  - For the treatment of cluster headaches, galcanezumab-gnlm demonstrated efficacy compared to placebo in an 8-week trial, which allowed for acute/abortive treatments during therapy. Galcanezumab-gnlm significantly decreased the mean change from baseline in weekly cluster headache attack frequency by 3.5 during weeks 1 to 3 vs placebo. Additionally, 18.8% more patients were classified as responders ( $\geq 50\%$  reduction in weekly cluster headache attack frequency) with galcanezumab-gnlm at week 3 vs placebo ( $p = 0.046$ ).
  - Ubrogepant and rimegepant are oral CGRP inhibitors FDA-approved for acute treatment of migraine with or without aura in adults. One differing characteristic is that ubrogepant allows for a second dose within 24 hours whereas rimegepant does not. **Additionally, ubrogepant allows for 2 dosing options (50 or 100 mg), and rimegepant allows for one (75 mg).**
    - **Rimegepant ODT demonstrated efficacy compared to placebo for acute use.** Patients were not allowed a second dose of study treatment (placebo or rimegepant). Rescue medications allowed 2 hours post-dose included aspirin, ibuprofen, naproxen (or any other type of NSAID), APAP up to 1000 mg/day, antiemetics (eg, metoclopramide or promethazine), or baclofen. Compared to placebo, significantly more patients treated with rimegepant were pain-free at 2 hours (difference vs placebo, 10.3%). For the co-primary endpoint of MBS, significantly more rimegepant-treated patients reported being MBS-free at 2 hours post-dose (difference vs placebo, 8.3%). **Additional trials evaluating the efficacy and safety of rimegepant were considered supportive for approval.**
    - **Ubrogepant demonstrated efficacy compared to placebo for acute response to migraine treatment after 2 hours.** A second dose of study treatment (placebo or ubrogepant), or the patient's usual acute treatment for migraine, was

allowed between 2 to 48 hours after the initial treatment for a non-responding or recurrent migraine headache. Compared to placebo, significantly more patients treated with ubrogepant were pain-free at 2 hours when administered the 50 mg (difference vs placebo, 7.4 to 7.5%) or 100 mg (difference vs placebo, 9.4%) dose. For the co-primary endpoint of MBS, significantly more ubrogepant-treated patients reported being MBS-free at 2 hours post dose for the 50 mg (difference vs placebo, 10.8 to 11.5%) and 100 mg (difference vs placebo, 9.9%) dose.

- Lack of information during pregnancy and breastfeeding is a consideration as many migraine patients are women of childbearing potential. The unknown risks of monoclonal antibodies and the effects on certain conditions are not fully characterized. Furthermore, rimegepant and ubrogepant have a number of drug interactions, and may not be appropriate with other medications. Important co-morbid populations were excluded from trials (eg, anxiety, depression, hypertension, and fibromyalgia), which also limits the generalizability to broader groups. There are no data in adolescents and children.
- The safety profiles of the subcutaneous CGRP inhibitors are generally mild with the most common adverse events observed being injection site reactions. Hypersensitivity and nasopharyngitis were the most commonly reported adverse events for the IV-administered agent, eptinezumab-jjmr. Mild to moderate hypersensitivity reactions, including rash, pruritus, drug hypersensitivity, and urticaria, were reported with all CGRP inhibitors. Post-marketing reports with erenumab-aooe have included hypertension and constipation with serious complications; some cases of constipation have required hospitalization and surgery. The oral CGRP inhibitors, ubrogepant and rimegepant, were associated with nausea; ubrogepant was additionally associated with somnolence.
- Overall for acute treatment, ubrogepant and rimegepant are alternatives to triptans and/or DHE in patients who are unable to tolerate or have an inadequate response or contraindication to established pharmacologic abortive migraine treatments. The injectable CGRP inhibitors represent another therapy option in the prevention of episodic or chronic migraine. Rimegepant is the only oral CGRP inhibitor that may be prescribed for the prevention of episodic migraines. Eptinezumab-jjmr and fremanezumab-vfrm are the only agents in the class that may be administered quarterly. Galcanezumab-gnlm is the only CGRP inhibitor indicated for the treatment of episodic cluster headaches. Dosage and administration vary by product and indication. Further long-term study is warranted.

## APPENDICES

### Appendix A. AAN levels of evidence classification (AAN 2017, Gronseth et al 2011)

Rating of recommendation	
A	Established as effective, ineffective, or harmful for the given condition in the specified population
B	Probably effective, ineffective, or harmful for the given condition in the specified population
C	Possibly effective, ineffective, or harmful for the given condition in the specified population
U	Data inadequate or conflicting; given current knowledge, treatment is unproven.
Rating of therapeutic article	
Class I	RCT in representative population with masked outcome assessment. The following are required: a) concealed allocation; b) primary outcome(s) is/are clearly defined; c) exclusion/inclusion criteria are clearly defined; d) adequate accounting for dropouts and crossovers with numbers sufficiently low to have minimal potential for bias; e) certain requirements are needed for noninferiority or equivalence trials claiming to prove efficacy for 1 or both drugs.
Class II	Cohort study that meets a–e (Class I) or RCT that lacks 1 criterion from above (b–e).
Class III	Controlled trials (including well-defined natural history controls or patients serving as own controls), a description of major confounding differences between groups, and where outcome assessment is independent of patient treatment.
Class IV	Does not include patients with the disease, different interventions, undefined/unaccepted interventions or outcomes measures, and/or no measures of effectiveness or statistical precision presented or calculable.

### Appendix B. AAN/AHS levels of evidence classification (Oskoui et al 2019[b])

Level of obligation; magnitude of benefit	
A	Must; large benefit relative to harm
B	Should; moderate benefit relative to harm
C	May; small benefit relative to harm
U	No recommendation supported; too close to call

## REFERENCES

- Aimovig [package insert], Thousand Oaks, CA: Amgen, Inc. and Novartis Pharmaceuticals Corp.; May 2021.
- AbbVie. U.S. FDA accepts AbbVie's new drug application for atogepant for the preventive treatment of migraine. AbbVie New Center. March 30, 2021. <https://news.abbvie.com/news/press-releases/us-fda-accepts-abbvies-new-drug-application-for-atogepant-for-preventive-treatment-migraine.htm> Accessed June 28, 2021.
- Ajovy [package insert], North Wales, PA: Teva Pharmaceuticals, Inc.; June 2021.
- American Migraine Foundation (AMF). Non-invasive neuromodulation devices. April 2, 2020. Web site. <https://americanmigrainefoundation.org/resource-library/neuromodulation-for-migraine-treatment/>. Accessed June 28, 2021.
- American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. *Headache*. 2019;59(1):1-18.
- Ashina M, Saper J, Cady R, et al. Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1). *Cephalalgia*. 2020;40(3):241-254.
- Berman G, Croop R, Kudrow D, et al. Safety of Rimegepant, an oral CGRP receptor antagonist, plus CGRP monoclonal antibodies for migraine. *Headache*. 2020; 60(8):1734-1742.
- Biohaven Pharmaceuticals. Zavegepant. 2021. <https://www.biohavenpharma.com/science-pipeline/cgrp/bhv-3500>. Accessed June 28, 2021.
- Burgos-Vega C, Moy J, Dussor G. Meningeal afferent signaling and the pathophysiology of migraine. *Prog Mol Biol Transl Sci*. 2015;131:537-64.
- Clinicaltrials.gov. US National Library of Medicine. 2021. Web site. <https://www.clinicaltrials.gov/>. Accessed June 28, 2021.
- Clinicaltrials.gov. A study of galcanezumab in participants with episodic cluster headache (NCT02397473). September 9, 2019. <https://www.clinicaltrials.gov/ct2/show/NCT02397473?term=NCT02397473&rank=1>. Accessed June 28, 2021.
- Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. *Lancet*. 2019;394(10200):737-745.
- Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. *Lancet*. 2021;397(10268):51-60.
- Detke, H, Goadsby PJ, Wang S, et al. Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study. *Neurology*. 2018;91(24):e2211-e2221.
- Diener H, Marmura MJ, Tepper SJ, et al. Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: subgroup analysis of PROMISE-2. *Headache*. 2021;61(1):125-136.
- Dodick DW, Ashina M, Brandes JL, et al. ARISE: A phase 3 randomized trial of erenumab-aooe for episodic migraine. *Cephalalgia*. 2018[a];38(6):1026-37.
- Dodick DW, Doty EG, Aurora SK, et al. Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine. *Cephalalgia*. 2021;41(3):340-352.
- Dodick DW, Silberstein SD, Bigal ME, et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial (HALO EM). *JAMA*. 2018[b];319(19):1999-2008.
- Dodick DW, Lipton RB, Ailani J, et al. Ubrogepant for the treatment of migraine. *N Engl J Med*. 2019;381(23):2230-2241.
- Drugs@FDA: FDA approved drug products. Food and Drug Administration Web site. <https://www.accessdata.fda.gov/scripts/cder/daf/>. Accessed June 28, 2021.
- Edvinsson L. The trigeminovascular pathway: role of CGRP and CGRP receptors in migraine. *Headache*. 2017;57 Suppl 2:47-55.
- Emgality [package insert], Indianapolis, IN: Eli Lilly and Company; December 2019.
- Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine - revised report of an EFNS task force. *Eur J Neurol*. 2009;16(9):968-981.
- Ferrari MD, Diener HC, Ning X, et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. *Lancet*. 2019;394(10203):1030-1040.
- Förderreuther S, Zhang Q, Stauffer VL, et al. Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies. *J Headache Pain*. 2018;19(1):121.
- Francis GJ, Becker WJ, Pringsheim TM. Acute and preventive pharmacologic treatment of cluster headache. *Neurology*. 2010;75:463-473.
- Global Burden of Disease (GBD) 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet*. 2016;388:1545-602.
- Goadsby PJ, Reuter U, Hallström Y, et al. A controlled trial of erenumab-aooe for episodic migraine (STRIVE). *N Engl J Med*. 2017;377(22):2123-32.
- Goadsby PJ, Dodick DW, Leone M, et al. Trial of galcanezumab in prevention of episodic cluster headache. *N Engl J Med*. 2019;381(2):132-141.
- Goadsby P, Reuter U, Hallstrom Y, et al. One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study. *Neurology*. 2020[a] Aug 4;95(5):e469-e479.
- Goadsby P, Silberstein S, Yeung P, et al. Long-term safety, tolerability, and efficacy of fremanezumab in migraine: A randomized study. *Neurology*. 2020[b] Nov 3;95(18):e2487-e2499.
- Gronseth GS, Woodroffe LM, Getchius TS, et al; for the American Academy of Neurology. Clinical Practice Guideline Process Manual, 11<sup>th</sup> edition. 2011. Available at: <http://tools.aan.com/globals/axon/assets/9023.pdf>. Accessed June 28, 2021.
- Hoffman J and May A. Diagnosis, pathophysiology, and management of cluster headache. *Lancet Neurol*. 2018;17(1):75-83.
- International Headache Society (IHS). Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. *Cephalalgia*. 2018;38(1):1-211.
- Katsarava Z, Buse DC, Manack AN, et al. Defining the differences between episodic migraine and chronic migraine. *Curr Pain Headache Rep*. 2012;16(1):86-92.
- Kudrow D, Cady RK, Allan B, et al. Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial. *BMC Neurol*. 2021;21:126.



- Lipton RB, Cohen JM, Bibeau K, et al. Reversion from chronic migraine to episodic migraine in patients treated with fremanezumab: post hoc analysis from HALO CM study. *Headache*. 2020[b];60(10):2444-2453.
- Lipton RB, Conway, CM, Stock, EG, et al. Efficacy, safety, and tolerability of rimegepant 75 mg, an oral CGRP receptor antagonist, for the treatment of migraine: Results from a phase 3, double-blind, randomized, placebo-controlled trial, Study 301. [poster]. Presented at the 60th Annual Scientific Meeting of the American Headache Society; San Francisco, CA; 2018.
- Lipton RB, Croop R, Stock EG, et al. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. *N Engl J Med*. 2019[c];381(2):142-149.
- Lipton RB, Dodick DW, Ailani J, et al. Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: The ACHIEVE II randomized clinical trial. *JAMA*. 2019[a];322(19):1887-1898.
- Lipton RB, Goadsby PJ, Smith J, et al. Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. *Neurology*. 2020[a];94(13):e1365-e1377.
- Lipton RB, Manack Adams A, Buse DC, et al. A comparison of the chronic migraine epidemiology and outcomes (CaMEO) study and American migraine prevalence and prevention (AMPP) study: demographics and headache-related disability. *Headache*. 2016;56:1280-9.
- Lipton RB, Tepper SJ, Reuter U, et al. Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study. *Neurology*. 2019[b];92(19):e2250-e2260.
- Ljubisavljevic S, Zidverc Trajkovic J. Cluster headache: pathophysiology, diagnosis and treatment. *J Neurol*. 2019;266(5):1059-1066.
- Manack AN, Buse DC, Lipton RB. Chronic migraine: epidemiology and disease burden. *Curr Pain Headache Rep*. 2011;15:70-8.
- Marcus R, Goadsby PJ, Dodick D, et al. BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. *Cephalalgia*. 2014;34(2):114-25.
- Marmura MJ, Silberstein SD, Schwedt TJ, et al. The acute treatment of migraine in adults: the American Headache Society evidence assessment of migraine pharmacotherapies. *Headache*. 2015;55(1):3-20.
- Mulleners W, Byung-Kun K, Lainex M, et al. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. *Lancet Neurol*. 2020 Oct;19(10):814-825.
- Mullin K, Kudrow D, Croop R, et al. Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy. *Neurology*. 2020;94(20):e2121-e2125.
- Nurtec ODT [dossier], New Haven, CT: Biohaven Pharmaceuticals; March 2020.
- Nurtec ODT [package insert], New Haven, CT: Biohaven Pharmaceuticals; May 2021.
- Orange Book: Approved drug products with therapeutic equivalence evaluations. Food and Drug Administration Web site. <https://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>. Accessed June 28, 2021.
- Oskoui M, Pringsheim T, Holler-Managan Y, et al. Practice guideline update summary: Acute treatment of migraine in children and adolescents: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society. *Neurology*. 2019[a];93(11):487-499.
- Oskoui M, Pringsheim T, Billingham L, et al. Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society. *Headache*. 2019[b];59(8):1144-1157.
- Purple Book: Database of Licensed Biological Products. US Food and Drug Administration. Updated June 25, 2021. <https://purplebooksearch.fda.gov/>. Accessed June 28, 2021.
- Reuter U, Goadsby PJ, Lanteri-Minet M, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. *Lancet*. 2018;392(10161):2280-7.
- Robbins MS, Starling AJ, Pringsheim TM, et al. Treatment of Cluster Headache: The American Headache Society Evidence-Based Guidelines. *Headache*. 2016;56(7):1093-106.
- Schwedt TJ, Kuruppu DK, Dong Y, Standley K, Yunes-Medina L, Pearlman E. Early onset of effect following galcanezumab treatment in patients with previous preventative medication failures. *J Headache Pain*. 2021;22(1):15.
- Silberstein SD. Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology*. 2000;55(6):754-762.
- Silberstein SD, Cohen JM, Seminario MJ, et al. The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study. *J Headache Pain*. 2020[b];21(1):114.
- Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the preventive treatment of chronic migraine (HALO CM). *N Engl J Med*. 2017;377(22):2113-22.
- Silberstein SD, Holland S, Freitag F, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. *Neurology*. 2012;78(17):1337-45. Reaffirmed July 18, 2015.
- Silberstein SD, Diamond M, Hindiyyeh N, et al. Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy-2) study. *J Headache Pain*. 2020[a];21(1):120.
- Simpson DM, Hallett M, Ashman EJ, et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. *Neurology*. 2016;86(19):1818-26. Reaffirmed May 7, 2019.
- Skljarevski V, Matharu M, Millen BA, et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. *Cephalalgia*. 2018;38(8):1442-54.
- Smith TR, Janelidze M, Chakhava G, et al. Eptinezumab for the prevention of episodic migraine: sustained effect through 1 year of treatment in the PROMISE-1 study. *Clin Ther*. 2020;42(12):2254-2265.e3.
- Starling AJ and Dodick DW. Best practices for patients with chronic migraine: burden, diagnosis, and management in primary care. *Mayo Clin Proc*. 2015;90(3):408-14.



- Stauffer VL, Dodick DW, Zhang Q, et al. Evaluation of galcanezumab for the prevention of episodic migraine: The EVOLVE-1 randomized clinical trial. *JAMA Neurol.* 2018;75(9):1080-8.
- Sun H, Dodick DW, Silberstein S, et al. Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Neurol.* 2016;15(4):382-90.
- Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab–aooe for preventive treatment of chronic migraine: a randomised, double–blind, placebo–controlled phase 2 trial. *Lancet Neurol.* 2017;16(6):425–34.
- Tepper SJ, Diener H, Ashina M, et al. Erenumab in chronic migraine with medication overuse: subgroup analysis of a randomized trial. *Neurology.* 2019;92(20):e2309-e2320.
- Teva Pharmaceutical press release. Teva bails on fremanezumab in cluster headache. April 23, 2019. <https://seekingalpha.com/news/3452826-teva-bails-fremanezumab-cluster-headache>. Accessed June 28, 2021.
- Ubrelvy [package insert], Madison, NJ: Allergan; **March 2021**.
- Vyepti [dossier], Bothell, WA: Lundbeck Pharmaceuticals; March 2020.
- Vyepti [package insert], Bothell, WA: Lundbeck Pharmaceuticals; February 2020.
- Walker CS and Hay DL. CGRP in the trigeminovascular system: a role for CGRP, adrenomedullin and amyline receptors? *Br J Pharmacol.* 2013; 170(7):1293-307.

Publication Date: June 30, 2021